GLP-1RAs are a relatively new class of injectables that are effective at reducing HbA 1c , have a low risk of hypoglycaemia when given as monotherapy or in the absence of sulphonylureas (SU) or insulin, and have the potential for weight losskey considerations when treating a typical obese patient with T2DM [4]
Xu J, Wei G, Wang J, Zhu J, Yu M, Zeng X, et al
Brains were dissected and paraffin-embedded, and 7-m coronal sections were stained with cresyl violet
J.HalestrapA
In their paper on the study, published in JAMA Ophthalmology , the researchers noted that the substantially increased risk of NAION observed in patients on semaglutide appears not to be due to differences in baseline characteristics between the cohorts. They proposed the possibility that expression of the GLP-1 receptor in the human optic nerve and GLP-1 RA-induced enhanced sympathetic nervous system activity might influence optic nerve head perfusion and potentially increase the risk of NAION. Another notable finding was that the greatest risk of NAION appeared to be within the first year following the prescription of semaglutide, a temporal association that supports a potential drug-induced risk of NAION, the researchers pointed out
These benefits are not trivial
